GLP-1 Agonists: What ED Clinicians Need to Know

GLP-1 receptor agonists commonly cause dose-dependent gastrointestinal toxicity because they slow gastric emptying and increase satiety signaling. In the ED, semaglutide, liraglutide, and tirzepatide matter not just for nausea and vomiting, but for dehydration, pre-renal AKI, pancreatitis, and biliary disease.

GLP-1 Agonists in Emergency Care

• Common drug names: Semaglutide, liraglutide, and tirzepatide are the key agents to recognize, with semaglutide appearing as Wegovy, Ozempic, and oral Rybelsus across obesity and diabetes indications.
• Mechanism behind symptoms: Delayed gastric emptying is the main pathophysiologic clue, explaining why nausea, vomiting, diarrhea, and early satiety dominate presentations rather than primary hypoglycemia.
• Weight-loss effectiveness: These drugs produce about 15% weight loss over 1 to 2 years, but substantial regain after discontinuation helps explain recurrent use, dose escalation, and repeat ED visits.
• High-risk adverse effects: Most complications are gastrointestinal, but severe volume loss can tip patients into hypotension and pre-renal AKI, especially early in therapy or after rapid dose escalation.
• Serious organ complications: Pancreatitis and gallbladder or biliary disease are the major can’t-miss diagnoses, with liraglutide carrying a notable pancreatitis signal. We get into the ED red flags in the episode.
• Hypoglycemia context: GLP-1 agonists alone rarely cause hypoglycemia; the risk rises mainly when they are paired with insulin or a sulfonylurea, which changes how reassuring a normal glucose should feel.

Access, Safety, and Patient Counseling

• Who should not use: Pregnancy, type 1 diabetes, prior hypersensitivity, and a personal or family history of MEN2 or medullary thyroid cancer are the major contraindication flags worth catching in the chart.
• Renal injury pathway: Pre-renal AKI usually comes from vomiting, diarrhea, and poor intake rather than direct nephrotoxicity, with higher risk in CKD and in patients taking ACE inhibitors or ARBs.
• Compounded drug concerns: Compounded semaglutide may use salt forms that are chemically different from FDA-approved products, creating real uncertainty about potency, sterility, and safety.
• Shortage-driven workarounds: National shortages and monthly prices often above $900 push patients toward online pharmacies, wellness clinics, and med spas. We lay out the bedside counseling points in the chapter.
• FDA sourcing advice: Patients should obtain these medications from licensed clinicians and FDA-registered, state-licensed pharmacies, and should avoid compounded versions when an approved product is available.

References:

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Available at https://www.cdc.gov/diabetes/data/statistics-report/index.html. Last updated June 29, 2022.
2. Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss [published online ahead of print, 2023 Oct 5]. JAMA. 2023;e2319574.  PMID: 37796527
3. Filippatos TD, et al. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014;11(3-4):202-230. PMID: 26177483
4. Liu L, et al. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789. Published 2022 Dec 7. PMID: 36568085
5. Shetty R, et al. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab Syndr. 2022;16(3):102427. PMID: 35217468
6. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. FDA. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014. Published June 04, 2021. 
7. Ozempic. https://www.novo-pi.com/ozempic.pdf. Accessed October 4, 2023.
8. Weygovy. https://www.novo-pi.com/wegovy.pdf. Accessed October 4, 2023.
9. RYBELSUS. https://www.novo-pi.com/rybelsus.pdf.  Accessed October 4, 2023.
10. Saxenda. https://www.novo-pi.com/saxenda.pdf. Accessed October 4, 2023.
11. Victoza. https://www.novo-pi.com/victoza.pdf. Accessed October 4, 2023.
12. Mounjaro. https://uspl.lilly.com/mounjaro/mounjaro.html#pi Accessed October 4, 2023.
13. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
14. Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100-109. PMID: 31539622
15. Davidson MH. Cardiovascular effects of glucagon like peptide-1 agonists. Am J Cardiol. 2011;108(3 Suppl):33B-41B. PMID: 21802579
16. Gallwitz B. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp Pharmacol. 2011;(203):53-74. PMID: 21484567
17. Zheng SL, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018;319(15):1580-1591. PMID: 29677303
18. Monami M, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909-917. PMID: 19318378
19. Grunvald E, Shah R, Hernaez R, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022;163(5):1198-1225. PMID: 36273831